newsfilter
← Latest News
GlobeNewswire·

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI